Prev Arrow Stocks

Amylyx Pharmaceuticals ($AMLX) Stock Forecast: Down 5.1% Today

Morpher AI identified a bearish signal. The stock price may continue to fall based on the momentum of the negative news.

What is Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) Market: The overall market for Amylyx Pharmaceuticals, Inc. experienced a strong bearish movement today.

Why is Amylyx Pharmaceuticals going down?

AMLX stock is down 5.1% on Nov 6, 2025 15:51

  • The bearish movement in AMLX could be attributed to a class action lawsuit against the company for securities fraud, likely causing uncertainty and negative sentiment among investors.
  • Concerns about the lawsuit's impact on the company's financial stability and reputation may have led to a sell-off of the stock.
  • An ongoing investigation into the claims against AMLX could have intensified pressure on the stock price, as uncertainty typically results in reduced investor confidence and a decline in stock value.

AMLX Price Chart

AMLX Technical Analysis

AMLX News

Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. ( NASDAQ: AMLX ) ; Avantor, Inc. ( NYSE: AVTR ) ; Humana Inc. ( NYSE: HUM ) ; and Maison Solutions Inc. ( NASDAQ: MSS ) : Grabar Law Office Investigates Claims on Your Behalf - Amylyx Pharmaceuticals ( NASDAQ:AMLX ) , Avantor ( NYSE:AVTR )

PHILADELPHIA, Nov. 06, 2025 ( GLOBE NEWSWIRE ) -- Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) - Class Action Survives Motion to Dismiss: Grabar Law Office is investigating claims on behalf of shareholders of Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) as securities fraud class action ...

https://www.benzinga.com/pressreleases/25/11/g48690236/notice-to-long-term-shareholders-of-amylyx-pharmaceuticals-inc-nasdaq-amlx-avantor-inc-nyse-avtr-h

0 News Article Image Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc.  ( NASDAQ: AMLX ) ; Avantor, Inc.  ( NYSE: AVTR ) ; Humana Inc.  ( NYSE: HUM ) ; and Maison Solutions Inc.  ( NASDAQ: MSS ) : Grabar Law Office Investigates Claims on Your Behalf - Amylyx Pharmaceuticals  ( NASDAQ:AMLX ) , Avantor  ( NYSE:AVTR )

Amylyx Pharmaceuticals Price History

17.08.2024 - AMLX Stock was up 10.3%

  • Recent executive purchases of shares in Reneo Pharmaceuticals and other stocks priced below $5 could signal optimism towards the pharmaceutical sector, potentially benefiting similar companies like AMLX.
  • The market's bullish trend, reflected in the Dow Jones index, likely created a favorable atmosphere for small-cap stocks such as AMLX to perform well.
  • The insider buying activity may have been viewed by investors and traders as a show of support for the industry, leading to increased interest in AMLX and driving its positive movement.

27.07.2025 - AMLX Stock was up 5.1%

  • AMLX stock surged as investors reacted positively to the company's strategic shift in focus from AMX0035 to avexitide and amyotrophic lateral sclerosis programs.
  • The decision to halt the Phase 2b trial for AMX0035 in progressive supranuclear palsy, despite showing no benefit over placebo, was seen as a prudent move by the company to reallocate resources to more promising programs.
  • The announcement of a cash runway through 2026 provided investors with confidence in the company's long-term sustainability and growth potential, contributing to the bullish sentiment surrounding AMLX stock today.

25.05.2025 - AMLX Stock was up 9.2%

  • AMLX displayed significant bullish movement in the market today.
  • The upward trend can be attributed to optimistic analyst views regarding the company's potential PBH treatment, which is estimated to target a $2 billion global market by 2035.
  • Investor enthusiasm is likely fueled by the anticipation of Avexitide's Phase 3 trial results in the first half of 2026 and the positive outcomes seen in Phase 2 trials.
  • Positive analyst initiations and coverage have also played a role in fostering a favorable outlook on AMLX, signaling increasing confidence in the company's future prospects.

18.10.2024 - AMLX Stock was up 7.1%

  • The bullish movement in AMLX could be attributed to positive analyst sentiment and upgrades in the online trading sector, similar to recent developments with other companies in the industry.
  • This change in outlook by analysts may have instilled confidence in investors, leading to increased buying activity and driving the stock price higher.
  • The overall optimism in the online trading industry, as indicated by the analyst upgrades, likely contributed to the positive momentum seen in AMLX today.

07.04.2025 - AMLX Stock was down 5.7%

  • A positive upgrade of Logitech International by a prominent Wall Street analyst possibly drew investor attention away from Amylyx Pharmaceuticals, resulting in a decline in AMLX shares.
  • The favorable outlook on Logitech International could have prompted a sector shift, with investors reallocating resources from pharmaceuticals like AMLX to technology-oriented firms.
  • The upgrade of Logitech International might have eclipsed any recent developments or announcements concerning Amylyx Pharmaceuticals, contributing to the stock's decline.
  • Investors may be adjusting their investment portfolios influenced by changing analyst evaluations, leading to a redirection of focus from AMLX to other companies with more favorable ratings.

14.06.2025 - AMLX Stock was up 5.3%

  • AMLX stock surged due to positive results from the Phase 2b trial of their drug avexitide, which showed a significant reduction in hypoglycemic events post-weight loss surgery.
  • The promising data from the trial likely boosted investor confidence in the drug's potential success in the market, leading to the bullish movement in AMLX stock.
  • The positive news overshadowed other market events such as the drop in PPI and Industrial Production, indicating that investors were primarily focused on the favorable trial results of avexitide.

06.10.2025 - AMLX Stock was down 5.1%

  • The bearish movement in AMLX could be attributed to a class action lawsuit against the company for securities fraud, likely causing uncertainty and negative sentiment among investors.
  • Concerns about the lawsuit's impact on the company's financial stability and reputation may have led to a sell-off of the stock.
  • An ongoing investigation into the claims against AMLX could have intensified pressure on the stock price, as uncertainty typically results in reduced investor confidence and a decline in stock value.

17.09.2025 - AMLX Stock was down 5.0%

  • The strong bearish movement in AMLX stock today could be attributed to profit-taking by investors after a period of solid earnings estimate revision activity.
  • Despite belonging to a strong industry, the stock may have faced selling pressure due to market volatility or broader economic concerns.
  • Investors might be reassessing their positions in AMLX stock, leading to a temporary decline in its market value.

12.02.2025 - AMLX Stock was up 12.4%

  • Amylyx Pharmaceuticals (AMLYX) experienced a strong bullish movement.
  • The positive market sentiment and the overall bullish trend in the market could have contributed to the surge in AMLYX stock.
  • There were no specific negative news related to AMLYX mentioned, indicating that the bullish movement might be more driven by market factors rather than company-specific news.
  • Investors might be optimistic about the future prospects of Amylyx Pharmaceuticals, leading to increased buying interest and pushing the stock price higher.

13.07.2024 - AMLX Stock was up 5.0%

  • AMLX stock experienced a strong bullish movement today.
  • The bullish trend can be attributed to the encouraging data revealed on the effects of AMX0035 on cerebrospinal fluid biomarkers related to Alzheimer's disease pathology and neurodegeneration.
  • The positive results from the Phase 2 trial, showing reduced tau levels and engagement of multiple pathological pathways, have likely boosted investor confidence in the potential of AMX0035 as a treatment for neurodegenerative diseases.
  • The company's recent financial report for Q2 2024 may have also contributed to the positive sentiment surrounding AMLX stock, indicating a strong pipeline with assets targeting orphan indications and FDA Breakthrough Therapy Designation for one of their drugs.

24.05.2025 - AMLX Stock was up 10.1%

  • Amylyx Pharmaceuticals (NASDAQ: AMLX) experienced a strong bullish movement today.
  • The upsurge in the stock's performance may be linked to a new analyst initiating a favorable outlook on the company.
  • Analyst Marcus Cole from UBS commencing coverage on a positive note possibly bolstered investor confidence in AMLX.
  • The optimistic analyst outlook likely played a role in driving the bullish momentum in AMLX's stock price during the day.

05.10.2025 - AMLX Stock was down 4.1%

  • An investigation into claims of securities fraud might have affected investor confidence in the company's operations and financial reporting.
  • The survival of the class action lawsuit could lead to legal and financial challenges for Amylyx Pharmaceuticals, creating uncertainty for investors.
  • Negative developments surrounding the company may have dampened market sentiment, overshadowing potential growth prospects and contributing to the bearish movement.
i
Disclaimer
Morpher is not liable for the content of the AI investment insights. Like most GPT-powered tools, these summaries may contain AI hallucinations and inaccurate information. Morpher is not presenting you with any investment advice. All investments involve risk, and the past performance of a security, industry, sector, market, or financial product does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. Such decisions should be based solely on an evaluation of their financial circumstances, investment objectives, risk tolerance, and liquidity needs. These summaries do not constitute investment advice.